Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis [4]

Leukemia

Volumn 21, Issue 8, 2007, Pages 1824-1826

  Bornhauser M ^a   Mohr, B ^a   Oelschlaegel, U ^a   Bornhauser P ^a   Jacki, S ^a   Ehninger, G ^a   Thiede, C ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; JANUS KINASE 2; LACTATE DEHYDROGENASE;

AGED; ANEMIA; BLOOD TOXICITY; BONE MARROW BIOPSY; CASE REPORT; CD34 SELECTION; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; MALE; MYELOFIBROSIS; MYELOID PROGENITOR CELL; MYELOPOIESIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPLENOMEGALY;

EID: 34447639429     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404730     Document Type: Letter

References (12)

1. Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999; 104 730-737.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
5. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676-3682.
6. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108: 346-352.
7. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920-2921.
8. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
9. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118-3122.
10. Blickstein D, Aviram A, Luboshitz J, Prokocimer M, Stark P, Bairey O et al. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: Clinical presentation. Blood 1997; 90: 2768-2771.
11. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
12. Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001; 20: 6188-6195.